- 期刊
Polyethylene Glycol（PEG）前處理可提昇高泌乳激素血症病患其血清泌乳激素之正確臨床檢驗數據
Polyethylene Glycol (PEG) Pretreatment Improves the Accuracy of Reporting Prolactin Results in Hyperprolactinemia
摘要
Objective: Marcoprolactin is a recently recognized high molecular mass complex (＞100 kDa), biologically inactive form of prolactin, which shows cross-reactivity with all current prolactin assays. Hyperprolactinemia due to unrecognized macroprolactinemia can lead to misdiagnosis and mismanagement. The aim of this study is to establish proper method such as using polyethylene glycol (PEG) pretreatment to remove macroprolactin for the accurate reporting of prolactin results in Hyperprolactinemia. Toward this aim, we used the ADVIA Centaur (Siemens Healthcare Diagnostics) and Architect i2000 (Abbott) instruments to assay serum prolactin following PEG pretreatment from 350 healthy volunteers to establish reference intervals. Moreover, such values were used to clinically categorize 217 individuals with hyperprolactinemia. Clinical symptoms of hyperprolactinemia were determined by chart review. The reference intervals for PEG pretreatment in male and female samples respectively, were (in ng/mL): 3.3-13.5, 3.4-19.5 (Centaur) and 3.8-17.8, 3.6-23.0 (Architect). For true hyperprolactinemic samples (n=199), PEG pretreatment decreased median prolactin values only from 55.0 to 44.5 ng/mL (Centaur) and 75.4 to 56.1 ng/mL (Architect), representing a 19% and a 26% drop, respectively for Centaur and Architect. In contrast, there was a significant drop in prolactin values from 30.0 to 11.9 ng/ml (Centaur) and 75.2 to 16.9 ng/mL (Architect) in macroprolactinemia (n=18), representing a 60% and a 78% drop, respectively for Centaur and Architect. Taken together, these data suggest that PEG pretreatment in hyperprolactinemic sera is a suitable method for measuring prolactin despite of macroprolactin interference.
並列摘要
Objective: Marcoprolactin is a recently recognized high molecular mass complex (＞100 kDa), biologically inactive form of prolactin, which shows cross-reactivity with all current prolactin assays. Hyperprolactinemia due to unrecognized macroprolactinemia can lead to misdiagnosis and mismanagement. The aim of this study is to establish proper method such as using polyethylene glycol (PEG) pretreatment to remove macroprolactin for the accurate reporting of prolactin results in Hyperprolactinemia. Toward this aim, we used the ADVIA Centaur (Siemens Healthcare Diagnostics) and Architect i2000 (Abbott) instruments to assay serum prolactin following PEG pretreatment from 350 healthy volunteers to establish reference intervals. Moreover, such values were used to clinically categorize 217 individuals with hyperprolactinemia. Clinical symptoms of hyperprolactinemia were determined by chart review. The reference intervals for PEG pretreatment in male and female samples respectively, were (in ng/mL): 3.3-13.5, 3.4-19.5 (Centaur) and 3.8-17.8, 3.6-23.0 (Architect). For true hyperprolactinemic samples (n=199), PEG pretreatment decreased median prolactin values only from 55.0 to 44.5 ng/mL (Centaur) and 75.4 to 56.1 ng/mL (Architect), representing a 19% and a 26% drop, respectively for Centaur and Architect. In contrast, there was a significant drop in prolactin values from 30.0 to 11.9 ng/ml (Centaur) and 75.2 to 16.9 ng/mL (Architect) in macroprolactinemia (n=18), representing a 60% and a 78% drop, respectively for Centaur and Architect. Taken together, these data suggest that PEG pretreatment in hyperprolactinemic sera is a suitable method for measuring prolactin despite of macroprolactin interference.